C. Huang, Y. Wang, and X. Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, vol.395, pp.497-506, 2020.

M. P. Lythgoe and P. Middleton, Ongoing Clinical Trials for the Management of the COVID-19 Pandemic, Trends Pharmacol Sci, vol.41, pp.363-382, 2020.

S. R. Bonam, S. V. Kaveri, A. Sakuntabhai, L. Gilardin, and J. Bayry, Adjunct immunotherapies for the management of severely ill COVID-19 patients, Cell Rep Med, vol.1, p.100016, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02555342

J. B. Wing, A. Tanaka, and S. Sakaguchi, Human FOXP3(+) Regulatory T cell heterogeneity and function in autoimmunity and cancer, Immunity, vol.50, pp.302-316, 2019.

N. Arpaia, J. A. Green, and B. Moltedo, A Distinct Function of Regulatory T Cells in Tissue Protection, Cell, vol.162, pp.1078-1089, 2015.

C. Qin, L. Zhou, and Z. Hu, Dysregulation of immune response in patients with COVID-19 in Wuhan, China, Clin Infect Dis, 2020.

F. Wang, H. Hou, and Y. Luo, The Laboratory tests and host immunity of COVID-19 patients with different severity of illness, JCI Insight, vol.5, p.137799, 2020.

G. Chen, D. Wu, and W. Guo, Clinical and immunological features of severe and moderate coronavirus disease 2019, J Clin Invest, vol.130, pp.2620-2629, 2020.

W. Wang, B. Su, and L. Pang, High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients, Cell Mol Immunol, vol.17, pp.650-652, 2020.

B. Kalfaoglu, J. Almeida-santos, and C. A. Tye, T-cell hyperactivation and paralysis in severeCOVID-19 infection revealed by single-cell analysis, 2020.

H. Chu, J. Zhou, B. H. Wong, and -. , Middle east respiratory syndrome coronavirus efficiently infects human primary t lymphocytes and activates the extrinsic and intrinsic apoptosis pathways, J Infect Dis, vol.213, pp.904-914, 2016.

D. Anghelina, J. Zhao, K. Trandem, and S. Perlman, Role of regulatory t cells in coronavirus-induced acute encephalitis, Virology, vol.385, pp.358-367, 2009.

M. Feuerer, L. Herrero, and D. Cipolletta, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters, Nat Med, vol.15, pp.930-939, 2009.

N. Wagner, G. Brandhorst, and F. Czepluch, Circulating regulatory t cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk, Obesity, vol.21, pp.461-468, 2013.

J. A. Bluestone, J. H. Buckner, and M. Fitch, Type 1 diabetes immunotherapy using polyclonal regulatory T cells, Sci Transl Med, vol.7, pp.315-189, 2015.

M. Romano, G. Fanelli, and C. A. Albany, Past, present, and future of regulatory t cell therapy in transplantation and autoimmunity, Front Immunol, vol.10, p.43, 2019.

A. Hartemann, G. Bensimon, and C. A. Payan, Low-dose interleukin 2 in patients with type 1 diabetes: A phase 1/2 randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, vol.1, pp.295-305, 2013.

E. Trotta, P. H. Bessette, and S. L. Silveria, A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism, Nat Med, vol.24, pp.1005-1014, 2018.

K. E. Webster, S. Walters, and R. E. Kohler, In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression, J Exp Med, vol.206, pp.751-760, 2009.

O. S. Qureshi, Y. Zheng, and K. Nakamura, Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4, Science, vol.332, pp.600-603, 2011.

M. Bonelli, L. Göschl, and S. Blüml, CTLA-4Ig) treatment reduces t cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis, Rheumatology, vol.55, pp.710-720, 2016.

K. Langdon and N. Haleagrahara, Regulatory T-cell dynamics with abatacept treatment in rheumatoid arthritis, Int Rev Immunol, vol.37, pp.206-214, 2018.

X. Michelena, H. Borrell, and M. López-corbeto, Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs, Semin Arthritis Rheum, vol.50, pp.564-570, 2020.

B. Fernandez-gutierrez, L. L. Madrid, and A. , Hospital admissions in inflammatory rheumatic diseases during the COVID-19 pandemic: incidence and role of disease modifying agents, vol.2020

E. Conticini, E. Bargagli, and M. Bardelli, COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs, Ann Rheum Dis, 2020.